Isolated hypoaldosteronism managed by DOCP in a dog with chronic kidney disease and hypercortisolism. Issue 6 (15th September 2022)

• Record Type: Journal Article
• Authors: Park, Su‐Min; An, Ju‐Hyun; Kim, Na‐Hyeong; Oh, Ye‐In; Seo, Kyoung‐won; Youn, Hwa‐Young
• Is Part Of: Veterinary medicine and science. Volume 8:Issue 6(2022)
• Page Start: 2292
• Page End: 2296
• Publication Date: 2022-09-15
• Subjects: chronic kidney disease -- deoxycorticosterone pivalate -- dog -- hypoaldosteronism -- trilostane; Veterinary medicine -- Periodicals; Animal Diseases; Veterinary medicine; Periodicals; Periodicals; 636.08905
• DOI: 10.1002/vms3.954
• Languages: English
• ISSNs: 2053-1095

Abstract

Abstract: A 13‐year‐old spayed female Schnauzer dog with chronic kidney disease (CKD; International Renal Interest Society stage 2, non‐proteinuric, normotensive), diabetes mellitus, hypercortisolism and myxomatous mitral valve degeneration (American College of Veterinary Internal Medicine stage B2) presented with electrolyte imbalance that had progressed to hyperkalaemia and hyponatremia, with a sodium to potassium (Na:K) ratio of 19.6. Cortisol levels after the adrenocorticotropic hormone stimulation test were within the therapeutic range, but aldosterone levels were below the reference range; hence, isolated hypoaldosteronism was diagnosed. After administration of deoxycorticosterone pivalate (DOCP), the electrolyte imbalance improved with a Na:K ratio of 27.7. This is the first report of the management of isolated hypoaldosteronism and hypercortisolism using trilostane and DOCP in a dog. This case highlights the importance of recognizing isolated hypoaldosteronism after long‐term treatment with trilostane in a canine patient with CKD. Abstract : This case highlights the importance of recognizing isolated hypoaldosteronism after long‐term treatment with trilostane in a CKD canine patient with hypercortisolism. In cases of isolated hypoaldosteronism, management with DOCP and continuous monitoring can lead to good outcomes.